Study protocol for THINK: a multinational open-label phase I study to assess the safety and clinical activity of multiple administrations of NKR-2 in patients with different metastatic tumour types

INTRODUCTION: NKR-2 are autologous T cells genetically modified to express a chimeric antigen receptor (CAR) comprising a fusion of the natural killer group 2D (NKG2D) receptor with the CD3ζ signalling domain, which associates with the adaptor molecule DNAX-activating protein of 10 kDa (DAP10) to pr...

Descripción completa

Detalles Bibliográficos
Autores principales: Lonez, Caroline, Verma, Bikash, Hendlisz, Alain, Aftimos, Philippe, Awada, Ahmad, Van Den Neste, Eric, Catala, Gaetan, Machiels, Jean-Pascal H, Piette, Fanny, Brayer, Jason B, Sallman, David A, Kerre, Tessa, Odunsi, Kunle, Davila, Marco L, Gilham, David E, Lehmann, Frédéric F
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2017
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5695348/
https://www.ncbi.nlm.nih.gov/pubmed/29133316
http://dx.doi.org/10.1136/bmjopen-2017-017075

Ejemplares similares

Ejemplares similares